1. Scrip
  2. >>Therapy Areas

Xoma Kills Gevokizumab, Reveals Another 44 Job Cuts

 
• By Mandy Jackson

Xoma Inc. finally stopped all development for gevokizumab, shifting its entire focus to endocrine diseases and cutting even more jobs, but the company somehow expects to sell the asset to another party after racking up another Phase III clinical trial failure.

Xoma Inc. finally stopped all development for gevokizumab, shifting its entire focus to endocrine diseases and cutting even more jobs, but the company somehow expects to sell the asset to another party after racking up another Phase III clinical trial failure.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

More from Therapy Areas

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.